15. Tabellenverzeichnis – Prostate Cancer

Version 6.2 · October 2021 · AWMF 043/022OL
Leitlinienprogramm Onkologie · Deutsche Krebsgesellschaft · Deutsche Krebshilfe · AWMF

Beteiligte Fachgesellschaften und Organisationen

Overview of absolute data on benefits and harms of PSA-assisted screening according to Schröder et al. 2014

Overview of risks identified in Lilja et al. 2011 and control intervals suggested by the authors of the study

Detection rate ratio (Drost et al. 2019)

Diagnostic precision in the detection of metastases (primary endpoint).

Weight of concomitant diseases contributing to the Charlson score (Charlson et al. 1987). The Charlson score is calculated by totaling a patient's scores

American Society of Anesthesiologists (ASA) health status classification (American Society of Anesthesiologists 2013)

Studies of prostate cancer under Active Surveillance with at least 5 years of median follow-up and at least 90 patients.

Morbidity and mortality after radical prostatectomy

Results of the three large RCTs on hypofractionation

LDR brachytherapy in noncomparative cohort studies

Cohort studies comparing LDR brachytherapy

Oncological endpoints of large cohort studies (n > 300) on HIFU in localized prostate cancer

Results (follow-up > 7 years) of collectives with cT3-cT4 treated with RPE

TNM classification (7th edition) for stages T3 and T4 (source: www.cancerstaging.org)

Results from the RCT TITAN on combination therapy with apalutamide, median observation time 22.7 months [Chi et al. 2019; Agarwal et al. 2019]

Results from the ARCHES RCTs on combination therapy with enzalutamide (median observation time 14.4 months) [Armstrong et al. 2019]

Results of RCT on combination therapy with abiraterone [Fizazi et al. 2017/2019; James et al. 2017]

Results of the RCT on combined hormone chemotherapy

Typical and common side effects of hormone ablative therapy and possibilities of prophylaxis and treatment to be communicated to the patient (based on Heidenreich 2007)

Prophylaxis and treatment of common side effects of chemotherapy in prostate cancer

WHO pain management scheme

Key questions and author groups

Changes in the recommendations after update 6 of 2021

Comparative overview of the side effect profile of prostate carcinoma treatments